List of Excipients in Branded Drug ANDRODERM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Allergan Inc	ANDRODERM	testosterone	0023-5990	ALCOHOL
Allergan Inc	ANDRODERM	testosterone	0023-5990	CARBOMER 1342
Allergan Inc	ANDRODERM	testosterone	0023-5990	GLYCERIN
Allergan Inc	ANDRODERM	testosterone	0023-5990	GLYCERYL OLEATE
Allergan Inc	ANDRODERM	testosterone	0023-5990	METHYL LAURATE
Allergan Inc	ANDRODERM	testosterone	0023-5990	SODIUM HYDROXIDE

Androderm Excipient Strategy and Commercial Opportunities

Last updated: August 8, 2026

Androderm was a testosterone transdermal system containing 2 mg/day or 4 mg/day of testosterone. Its excipient platform used an alcohol-based reservoir with hydroxypropyl cellulose, glycerin, and sodium hydroxide, combined with a multilayer patch incorporating a backing film, rate-controlling membrane, and adhesive system.[1] The product has been discontinued in the United States, creating an opportunity for improved testosterone patches, but the commercial case depends on skin tolerability, adhesion, dose consistency, controlled-substance compliance, and differentiation from generic testosterone gels.

What excipients did Androderm contain?

Androderm's drug reservoir used a small excipient system designed to dissolve testosterone and support delivery across the skin.

Component	Function in Androderm
Alcohol	Solvent for testosterone; supports evaporation and skin partitioning
Hydroxypropyl cellulose	Reservoir thickener and viscosity modifier
Glycerin	Humectant and solvent-support excipient
Sodium hydroxide	pH adjustment and formulation control
Polyester backing film	Protects the reservoir and controls patch handling
Ethylene-vinyl acetate membrane	Controls drug release from the reservoir
Adhesive layer	Fixes the patch to the skin during wear

The FDA label identifies alcohol, hydroxypropyl cellulose, glycerin, and sodium hydroxide as inactive ingredients in the testosterone reservoir.[1] The product's delivery performance depended on the complete system, not the reservoir alone. The membrane, adhesive, backing layer, patch dimensions, reservoir loading, and application site all affected the delivered dose.

Why was the excipient platform commercially relevant?

Testosterone has limited passive skin permeability. The Androderm system therefore needed to balance four variables:

1. Adequate testosterone flux through the skin.
2. Controlled delivery over the intended 24-hour wear period.
3. Acceptable adhesion during movement, perspiration, and bathing.
4. Low rates of erythema, itching, and contact dermatitis.

Alcohol can improve testosterone solubilization and skin permeation, but it can also increase dryness and irritation. Glycerin can moderate drying effects but may change reservoir viscosity and water activity. Hydroxypropyl cellulose improves physical stability but can alter release kinetics if its concentration or molecular weight changes. Sodium hydroxide provides pH control but must be tightly managed because pH can affect skin tolerability and formulation stability.

The commercial lesson is that excipient selection cannot be separated from patch architecture. A reformulated reservoir using the same ingredients may still produce a different drug-release profile if the membrane, adhesive, reservoir thickness, or backing film changes.

What excipient opportunities exist for an Androderm successor?

The strongest opportunities are improved tolerability, lower skin residue, better adhesion, and more consistent delivery.

Low-irritation reservoir systems

A successor could reduce reliance on high alcohol content by using a mixed-solvent system or a more efficient testosterone solubilizer. Candidate approaches include:

• Lower alcohol concentration with optimized polymer viscosity.
• Alternative co-solvents compatible with transdermal use.
• Reduced alkalinity through tighter pH control.
• Hydrophilic polymer systems that limit reservoir migration.
• Lower-residue formulations that reduce post-removal cleanup.

Any replacement solvent must preserve testosterone solubility, membrane compatibility, chemical stability, and skin safety. A lower-alcohol system that crystallizes during storage would not provide a viable commercial improvement.

Adhesive innovation

Adhesive performance is a major opportunity because patch failure directly affects dose delivery and patient persistence.

Potential platforms include:

• Silicone adhesives for sensitive skin and lower extraction of testosterone.
• Acrylate adhesives with stronger initial tack.
• Hybrid silicone-acrylate systems.
• Perimeter adhesives that isolate the drug reservoir from direct skin contact.
• Low-trauma adhesives designed for repeated daily removal.
• Adhesive systems with reduced interaction with sweat and sebum.

A new adhesive can create freedom-to-operate value if it changes the delivery system materially. It also introduces regulatory risk because adhesive composition, skin contact, extractables, leachables, and irritation studies may require substantial characterization.

Matrix and drug-in-adhesive systems

Androderm used a reservoir-based design. A matrix or drug-in-adhesive patch could reduce manufacturing complexity and patch thickness. It may also improve flexibility and reduce leakage risk.

The tradeoff is dose control. A reservoir system separates the drug formulation from the adhesive and can provide stronger control over release. A matrix system may be easier to manufacture but can show more direct dependence on adhesive composition, drug crystallization, skin hydration, and temperature.

A differentiated product could use:

• A low-load matrix patch for reduced skin exposure.
• A multilayer matrix with a separate rate-controlling film.
• A small-format patch with higher flux.
• A once-weekly system if sustained delivery is technically achievable.
• A patch designed for application to less visible body sites.

These systems could support composition-of-matter, system, manufacturing, and method-of-use patent claims.

What patents protected Androderm and are they still relevant?

The principal Androderm patent opportunity is historical rather than based on a clearly active U.S. product patent estate.

Foundational transdermal testosterone patents included patents directed to testosterone delivery through the skin and related patch technologies, including U.S. Patent Nos. 5,023,095 and 5,152,997. Those patents are now expired based on their filing and issue timelines. The original Androderm platform therefore does not appear to have a meaningful remaining U.S. patent barrier based solely on its basic testosterone patch concept.[2][3]

IP category	Historical relevance	Current commercial value
Testosterone transdermal composition	Covered early solvent and delivery concepts	Low if expired
Reservoir patch architecture	Covered controlled-release patch construction	Low for broad legacy claims
Adhesive and membrane system	Could support narrower product claims	Potentially relevant only for new designs
Manufacturing process	May protect loading, sealing, or coating steps	Relevant if a new process is proprietary
Application method	May cover dosing or application-site protocols	Potentially relevant for differentiated labeling
New excipient combination	Could support formulation claims	Most promising route for new IP
New patch geometry or wear schedule	Could support device and method claims	Commercially useful if clinically meaningful

A new entrant should focus on new, technically defensible claims rather than attempting to revive expired broad claims covering testosterone patches generally. The most valuable claim scope would likely cover a defined excipient concentration range, adhesive chemistry, release profile, patch construction, stability profile, or skin-irritation performance.

What formulation patents could protect a successor?

Potential claim categories include:

• Testosterone plus a specified solvent system.
• Testosterone, hydroxypropyl cellulose, and a defined humectant ratio.
• A low-irritation reservoir with a controlled pH range.
• A testosterone matrix with a defined adhesive polymer.
• A patch that delivers a specified testosterone amount over 24 hours.
• A patch with a defined residual drug percentage after wear.
• A formulation that limits testosterone crystallization.
• A patch with improved adhesion after showering or exercise.
• A packaging system that controls alcohol loss during shelf life.

Patent strength will depend on unexpected technical results. A patent application that merely substitutes one conventional transdermal excipient for another may face obviousness challenges. Comparative data showing reduced dermatitis, improved adhesion, better dose uniformity, or longer stability would materially strengthen the estate.

When did Androderm lose exclusivity and what is its FDA status?

Androderm was approved in the United States under NDA 020489. The FDA-approved product was a testosterone transdermal system in 2 mg/day and 4 mg/day strengths.[1][4]

The product is listed as discontinued in U.S. FDA product databases. The discontinuation is distinct from a finding that the product was withdrawn for safety or efficacy reasons.[4] The relevant commercial issue is that Androderm is no longer an actively marketed U.S. branded product, while testosterone remains an established controlled prescription therapy.

Milestone	Status
Active ingredient	Testosterone
Dosage form	Transdermal system
U.S. strengths	2 mg/day and 4 mg/day
FDA application	NDA 020489
U.S. marketing status	Discontinued
Orange Book relevance	Historical NDA listing; no current branded commercial franchise
Regulatory exclusivity	Expired
Foundational patch patents	Expired
Controlled substance status	Testosterone is Schedule III under federal law

The Orange Book does not create a current commercial barrier for a new testosterone patch comparable to an active blockbuster franchise. A new product would instead face formulation, clinical, manufacturing, and market-access barriers.

What FDA pathway would a new Androderm-like product use?

A product that is pharmaceutically equivalent and therapeutically equivalent to the reference product could pursue an abbreviated pathway, but a discontinued reference product can complicate the practical availability of an ANDA route. A materially different patch, excipient system, delivery profile, or indication may require a 505(b)(2) application.

ANDA considerations

An ANDA candidate would need to address:

• Same active ingredient.
• Same dosage form and route.
• Equivalent strength.
• Pharmaceutical equivalence.
• Bioequivalence.
• Product-specific performance requirements.
• Adhesion and irritation characteristics.
• Packaging and stability.
• Controlled-substance compliance.

For a transdermal system, conventional plasma pharmacokinetic equivalence may not capture all clinically relevant performance differences. Adhesion, residual drug, skin irritation, adhesion after water exposure, and delivery consistency can become important development issues.

505(b)(2) considerations

A 505(b)(2) strategy is more suitable when the sponsor changes:

• Patch architecture.
• Excipients.
• Application site.
• Wear duration.
• Dose schedule.
• Delivery rate.
• Indication or patient population.
• Manufacturing process with clinical impact.

This route can support a differentiated product but typically requires more clinical and technical evidence than a straightforward generic strategy.

What Paragraph IV challenges could affect Androderm competition?

Paragraph IV litigation risk would primarily arise if a new applicant certifies that an Orange Book-listed patent for a reference product is invalid, unenforceable, or not infringed. Because Androderm is discontinued and its foundational patent estate is old, the risk from legacy Androderm patents appears limited.

A new branded successor could create a fresh Paragraph IV target by listing patents covering:

• New excipient combinations.
• New adhesive systems.
• New patch geometries.
• Extended wear schedules.
• Improved pharmacokinetic profiles.
• Manufacturing controls.
• Methods for treating hypogonadism with a defined delivery schedule.

The commercial risk would increase if those patents are listed against an actively marketed NDA and if the product captures substantial reimbursement share. A sponsor should avoid relying on weak, broad claims that invite early invalidity challenges.

What generic launch risks exist for a testosterone patch?

The largest launch risks are technical and commercial rather than basic patent blocking.

Technical risks

Patch products can fail through:

• Variable skin permeability.
• Poor adhesion.
• Edge lifting.
• Reservoir leakage.
• Alcohol loss during storage.
• Testosterone crystallization.
• Dose variability after temperature excursions.
• Skin irritation.
• Manufacturing variability in membrane thickness.
• Inconsistent coating weight.

These risks can delay approval and increase batch-release costs.

Regulatory risks

Testosterone is a controlled substance. A sponsor must manage DEA registration, inventory controls, diversion controls, prescription monitoring requirements, and supply-chain security.[5] The label must also address transfer risk, virilization risk, misuse, abuse, and contraindications relevant to testosterone therapy.

Commercial risks

A patch competes with low-cost generic testosterone gels, branded gels, injectable testosterone, oral testosterone undecanoate, and implantable formulations. Gels have established prescribing familiarity and broad distribution. Injections often have lower acquisition cost. A patch must justify its price through convenience, reduced transfer risk, improved adherence, or a specific tolerability advantage.

How does Androderm compare with testosterone gels and injections?

Product category	Main advantage	Main weakness	Excipient opportunity
Testosterone patch	No daily gel rubbing; controlled skin delivery	Adhesion and dermatitis	Low-irritation adhesive and improved wear
Testosterone gel	Flexible dosing; established market	Transfer risk; daily application	Lower-residue, faster-drying gel
Injectable testosterone	Low unit cost; high systemic exposure	Peaks, troughs, injection burden	Long-acting depot delivery
Oral testosterone undecanoate	Oral administration	Food dependence and cost	Improved absorption and reduced variability
Implantable testosterone	Long dosing interval	Procedure required	Longer duration and simpler insertion

Androderm's commercial opportunity is strongest among patients who prefer noninjection therapy but do not want gel transfer risk. The product must also overcome the perception that patches cause more skin reactions than gels.

Which companies are challenging the testosterone transdermal market?

The competitive field includes manufacturers of generic testosterone gels and patches, branded testosterone products, and long-acting injectable therapies. Important market participants have included AbbVie, Endo Pharmaceuticals, Viatris, Hikma, Perrigo, and other generic manufacturers, although product availability varies by jurisdiction and time.

The competitive landscape is fragmented. No single excipient strategy dominates testosterone replacement therapy. Commercial success depends on reimbursement, prescriber familiarity, pharmacy access, patient preference, and repeat-use tolerability.

A new Androderm-style product could compete through:

• A smaller and more discreet patch.
• A lower-irritation adhesive.
• A 24-hour patch with fewer application failures.
• Reduced testosterone residue after removal.
• A lower-cost generic presentation.
• A co-packaged skin-preparation system.
• A payer-focused product with demonstrated persistence.

What licensing and partnering opportunities exist?

Licensing value would center on platform technology rather than the discontinued Androderm brand.

Potential assets include:

• Testosterone-compatible silicone or hybrid adhesives.
• High-flux transdermal delivery systems.
• Low-irritation permeation enhancers.
• Alcohol-retaining patch reservoirs.
• Manufacturing technology for uniform drug-in-adhesive coatings.
• Packaging that reduces solvent loss.
• Wear-time monitoring or adherence technologies.
• Regional rights for testosterone transdermal products.

A licensee would likely require freedom-to-operate analysis covering adhesive polymers, membranes, permeation enhancers, patch construction, and manufacturing equipment. The deal structure could include an upfront payment, development milestones, regulatory milestones, and tiered royalties based on net sales.

How strong is the Androderm patent estate?

The legacy Androderm estate is weak as a current blocking position because the foundational testosterone transdermal patents have expired and the branded product is discontinued. Its technical disclosures remain valuable as prior art and as a development benchmark.

A new sponsor can build a stronger estate around measurable improvements:

• Lower dermatitis rates.
• Higher percentage of successful wear periods.
• Consistent 24-hour testosterone exposure.
• Reduced residual drug.
• Longer shelf life.
• Lower manufacturing waste.
• Improved stability under elevated temperature and humidity.
• New application sites or wear schedules.

The strongest protection would combine formulation, device, process, and method-of-use claims. A single formulation patent would be easier to design around.

Key Takeaways

• Androderm used an alcohol-based testosterone reservoir containing hydroxypropyl cellulose, glycerin, and sodium hydroxide.
• The product's performance depended on the full patch system, including the membrane and adhesive.
• Androderm is discontinued in the United States, and its regulatory exclusivity has expired.
• Foundational testosterone transdermal patents are historical and do not appear to block a new U.S. entrant.
• The best commercial opportunity is an improved patch with lower irritation, stronger adhesion, lower residue, and reliable dose delivery.
• A new product would likely require an ANDA or 505(b)(2) strategy, depending on formulation and device differences.
• Testosterone's Schedule III status creates material manufacturing, distribution, and compliance obligations.
• New patents should focus on excipient combinations, adhesive systems, release performance, stability, and clinically demonstrated tolerability.

FAQs

Can a company relaunch Androderm using the original excipients?

A company could develop a testosterone patch using the historical excipient concept, but it would need to establish regulatory acceptability, manufacturing controls, stability, bioequivalence or clinical performance, and controlled-substance compliance. Reusing the same excipients would not automatically provide regulatory equivalence.

Is hydroxypropyl cellulose still a viable excipient for testosterone patches?

Yes. Hydroxypropyl cellulose remains a practical viscosity modifier and reservoir polymer, but its suitability depends on molecular weight, concentration, solvent compatibility, membrane interaction, and release performance. It is unlikely to provide strong differentiation without supporting formulation data.

What is the most valuable excipient improvement for a testosterone patch?

A lower-irritation adhesive or reservoir system with verified delivery consistency is likely to have the highest commercial value. Patients may accept a premium for a patch that remains attached during daily activity and causes fewer skin reactions.

Could a testosterone patch receive three-year clinical exclusivity?

A 505(b)(2) product may qualify for three-year exclusivity if it relies on new clinical investigations essential to approval. The exclusivity would protect the approved change, not necessarily the underlying testosterone molecule or every testosterone patch.

Are biosimilars relevant to Androderm?

No. Testosterone is a small-molecule active ingredient, not a biologic. Competitive entry would occur through generic or 505(b)(2) pathways rather than biosimilar approval.

References

1. U.S. Food and Drug Administration. (2016). Androderm testosterone transdermal system prescribing information. NDA 020489.

2. U.S. Patent No. 5,023,095. (1991). Transdermal administration of testosterone. United States Patent and Trademark Office.

3. U.S. Patent No. 5,152,997. (1992). Transdermal administration of testosterone. United States Patent and Trademark Office.

4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Androderm, NDA 020489. FDA.

5. U.S. Drug Enforcement Administration. (n.d.). Controlled substances schedules. U.S. Department of Justice.